Indo-National Q3 FY26: Standalone Net Loss ₹661.95 Lakhs, Revenue ₹10,611.30 Lakhs
Indo-National Limited reported Q3 FY26 unaudited standalone revenue of ₹10,611.30 Lakhs and a net loss of ₹661.95 Lakhs. Consolidated revenue was ₹10,630.91 Lakhs with a net loss of ₹1215.03 Lakhs. The company invested ₹568.66 Lakhs in Medcuore Medical Solutions, making it a subsidiary, and ₹850 Lakhs in Axial Aero.
The reported losses and declining revenues are material financial events that can impact investor sentiment and the company's valuation. However, ongoing investments and strategic initiatives like amalgamation might mitigate some negative impact in the long term.
The company reported a significant net loss for the quarter on both standalone and consolidated bases, a reversal from profits in the previous year's comparable quarter. Revenue also saw a decline.
Indo-National Limited announced its unaudited standalone and consolidated financial results for the quarter ended December 31, 2025. The Board of Directors, in a meeting held on February 4, 2026, approved these results. The company reported a standalone revenue from operations of ₹10,611.30 Lakhs for the quarter, a decrease from ₹12,163.30 Lakhs in the same period last year. The standalone net loss for the quarter was ₹661.95 Lakhs, compared to a profit of ₹63.18 Lakhs in the prior year's quarter. For the nine months ended December 31, 2025, the standalone revenue from operations stood at ₹34,462.22 Lakhs, with a net loss of ₹231.68 Lakhs. The consolidated revenue from operations for the quarter was ₹10,630.91 Lakhs, with a net loss of ₹1215.03 Lakhs. The consolidated nine-month revenue was ₹34,534.81 Lakhs, with a net loss of ₹1215.03 Lakhs. During the nine months, the company made significant investments, including ₹568.66 Lakhs for acquiring a 46.76% stake in Medcuore Medical Solutions Private Limited, making it a subsidiary. Additionally, ₹850 Lakhs was invested in Compulsory Convertible Preference Shares of Axial Aero Private Limited. The company also mentioned an ongoing application for the amalgamation of its wholly-owned subsidiary, Helios Strategic Systems Limited, with Indo-National Limited, with no objections reported so far. In a separate legal matter, the company is appealing a penalty imposed by the CCI related to cartelization, having deposited 10% of the penalty amount as per NCLAT's order. The New Labour Codes became effective, resulting in a past period employee benefit liability recognized for ₹86.00 Lakhs (standalone) and ₹87.00 Lakhs (consolidated).
What to do with a filing like this
Indo-National Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Indo-National Limited. Read the original for the full detail.